We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Standalone HPV Testing Recommended for Cervical Cancer Screening

By LabMedica International staff writers
Posted on 02 Oct 2018
The number of deaths from cervical cancer in the USA has decreased substantially since the implementation of widespread cervical cancer screening and has declined from 2.8 to 2.3 deaths per 100,000 women from 2000 to 2015.

The evidence on screening for cervical cancer has been reviewed with a focus on clinical trials and cohort studies that evaluated screening with high-risk human papillomavirus (hrHPV) testing alone or hrHPV and cytology together (co-testing) compared with cervical cytology alone.

The US Preventive Services Task Force (Rockville, MD, USA) besides reviewing and evaluating cervical cancer screening also commissioned a decision analysis model to evaluate the age at which to begin and end screening, the optimal interval for screening, the effectiveness of different screening strategies, and related benefits and harms of different screening strategies.

The experts reported on screening with cervical cytology alone, primary hrHPV testing alone, or co-testing can detect high-grade precancerous cervical lesions and cervical cancer. More...
Screening women aged 21 to 65 years substantially reduces cervical cancer incidence and mortality. The harms of screening for cervical cancer in women aged 30 to 65 years are moderate. Four studies identified in the review found that primary hrHPV testing detected higher rates of stage 3 (or worse) cervical intraepithelial neoplasia compared with the standalone Pap test in the first round of testing. In comparing the Pap, hrHPV and co-testing methods, the latter two methods were associated with higher colposcopy and false-positive rates.

The scientists concluded with high certainty that the benefits of screening every three years with cytology alone in women aged 21 to 29 years substantially outweigh the harms. They also concluded with high certainty that the benefits of screening every three years with cytology alone, every five years with hrHPV testing alone, or every five years with both tests (co-testing) in women aged 30 to 65 years outweigh the harms. Screening women older than 65 years who have had adequate prior screening and women younger than 21 years does not provide significant benefit. The anticipation is hrHPV testing every five years for women aged 30 to 65 could reduce cervical cancer mortality from 8.34 to 0.29 deaths per 1,000 women.

Lee A. Learman, MD, PhD, professor of obstetrics and gynecology, said, “HPV testing every five years is an attractive option for patients who want to avoid pelvic exams and Pap smears. The Pap test is well known and accepted by patients and women’s healthcare providers, and there would need to be powerful incentives to move away from it. Switching from Pap tests annually to every three years has been the USPSTF recommendation since 2012, but patient and provider preferences have been hard to change. I expect the same phenomenon will delay implementation of primary HPV screening every 5 years.” The study was published on August 21, 2018, in the Journal of the American Medical Association.

Related Links:
US Preventive Services Task Force


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
New
Automated Immunoassay Analyzer
SuperFlex™
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.